Tempus AI (NASDAQ:TEM - Get Free Report) was downgraded by research analysts at TD Cowen from a "buy" rating to a "hold" rating in a note issued to investors on Tuesday,Finviz reports. They currently have a $88.00 target price on the stock. TD Cowen's price objective would suggest a potential downside of 4.81% from the stock's previous close.
A number of other brokerages also recently issued reports on TEM. Bank of America boosted their price objective on Tempus AI from $68.00 to $70.00 and gave the company a "neutral" rating in a research note on Wednesday, June 25th. HC Wainwright boosted their price objective on Tempus AI from $90.00 to $98.00 and gave the company a "buy" rating in a research note on Friday, September 12th. Piper Sandler reissued a "neutral" rating on shares of Tempus AI in a research note on Friday, August 8th. Morgan Stanley boosted their price objective on Tempus AI from $65.00 to $68.00 and gave the company an "overweight" rating in a research note on Tuesday, August 12th. Finally, Cowen lowered Tempus AI from a "buy" rating to a "hold" rating in a research report on Tuesday. Seven analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $75.85.
View Our Latest Report on TEM
Tempus AI Trading Up 5.3%
Shares of TEM stock opened at $92.45 on Tuesday. The firm has a market capitalization of $16.06 billion, a P/E ratio of -77.69 and a beta of 4.87. Tempus AI has a twelve month low of $31.36 and a twelve month high of $104.32. The company has a quick ratio of 1.43, a current ratio of 1.54 and a debt-to-equity ratio of 2.58. The stock's fifty day simple moving average is $82.82 and its 200 day simple moving average is $66.72.
Tempus AI (NASDAQ:TEM - Get Free Report) last announced its earnings results on Friday, August 8th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01. The firm had revenue of $314.64 million for the quarter, compared to the consensus estimate of $296.84 million. Tempus AI had a negative return on equity of 122.86% and a negative net margin of 20.98%.The business's quarterly revenue was up 89.5% compared to the same quarter last year. During the same period in the previous year, the business earned ($6.86) EPS. Tempus AI has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Tempus AI will post -6.15 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, Director Theodore Leonsis sold 44,000 shares of the stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $69.90, for a total value of $3,075,600.00. Following the transaction, the director owned 86,756 shares of the company's stock, valued at $6,064,244.40. This represents a 33.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Eric P. Lefkofsky sold 332,500 shares of the business's stock in a transaction dated Thursday, September 25th. The shares were sold at an average price of $76.56, for a total value of $25,456,200.00. Following the completion of the sale, the chief executive officer directly owned 9,141,032 shares of the company's stock, valued at approximately $699,837,409.92. This trade represents a 3.51% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 933,662 shares of company stock valued at $68,070,993 over the last quarter. Insiders own 26.27% of the company's stock.
Institutional Trading of Tempus AI
A number of institutional investors have recently modified their holdings of TEM. Cranbrook Wealth Management LLC purchased a new stake in Tempus AI in the third quarter worth about $25,000. GAMMA Investing LLC purchased a new stake in Tempus AI in the third quarter worth about $28,000. Concord Wealth Partners lifted its holdings in Tempus AI by 308.0% in the second quarter. Concord Wealth Partners now owns 408 shares of the company's stock worth $26,000 after buying an additional 308 shares during the period. Allworth Financial LP lifted its holdings in Tempus AI by 5,000.0% in the second quarter. Allworth Financial LP now owns 459 shares of the company's stock worth $29,000 after buying an additional 450 shares during the period. Finally, SouthState Corp lifted its holdings in Tempus AI by 3,761.5% in the second quarter. SouthState Corp now owns 502 shares of the company's stock worth $32,000 after buying an additional 489 shares during the period. 24.22% of the stock is currently owned by hedge funds and other institutional investors.
Tempus AI Company Profile
(
Get Free Report)
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tempus AI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.
While Tempus AI currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.